Elan Corporation, plc (ELN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (6262)	1/18/2005 1:41:29 AM
From: fred hayes	Read Replies (3) of 10345

Drum roll please (you won't see this very often): I think both IJ and Peter have it wrong. Copaxone will be the drug that suffers most from T. It seems to me that patients on C are there because it's not an interferon, and/or it has limited side effects. Well, T is not an interferon, and has very limited side effects. And looks much more effective. Say goodbye, C. R is supposed to be most effective interferon, but that looks to be true only because it's higher dose of same drug as A. A won't suffer as much as R because of the combo data. Bottom line, C suffers most; then R; then A... Disclaimer: I usually don't know what I'm talking about (:>). add/edit: Ranking after the dust settles: T ( > half the market), then A, R, and C. fred

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next